Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Analysts at Piper Jaffray Companies lowered their Q1 2020 earnings estimates for Endo International in a research report issued to clients and investors on Thursday, May 9th, according to Zacks Investment Research. Piper Jaffray Companies analyst D. Amsellem now expects that the company will earn $0.49 per share for the quarter, down from their previous forecast of $0.50. Piper Jaffray Companies has a “Hold” rating on the stock. Piper Jaffray Companies also issued estimates for Endo International’s Q2 2020 earnings at $0.55 EPS and FY2020 earnings at $2.29 EPS.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, May 9th. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.11. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The business had revenue of $720.00 million during the quarter, compared to the consensus estimate of $692.31 million. During the same period last year, the company earned $0.67 earnings per share. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year.
Other analysts also recently issued reports about the company. BidaskClub upgraded Endo International from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. SunTrust Banks began coverage on Endo International in a report on Tuesday, March 19th. They issued a “buy” rating and a $13.00 price objective for the company. Canaccord Genuity set a $17.00 price objective on Endo International and gave the company a “buy” rating in a report on Friday, March 8th. ValuEngine upgraded Endo International from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. Finally, Zacks Investment Research upgraded Endo International from a “sell” rating to a “hold” rating in a report on Tuesday, February 26th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have given a buy rating to the company. Endo International presently has an average rating of “Hold” and an average price target of $14.88.
NASDAQ:ENDP opened at $6.52 on Monday. Endo International has a twelve month low of $5.92 and a twelve month high of $18.50. The firm has a market cap of $1.47 billion, a PE ratio of 2.26 and a beta of 1.12.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank purchased a new position in Endo International in the fourth quarter valued at about $21,218,000. Geode Capital Management LLC grew its stake in Endo International by 8.8% in the first quarter. Geode Capital Management LLC now owns 2,666,043 shares of the company’s stock valued at $21,407,000 after purchasing an additional 214,518 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Endo International by 1.1% in the fourth quarter. Bank of New York Mellon Corp now owns 2,540,603 shares of the company’s stock valued at $18,546,000 after purchasing an additional 27,353 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Endo International by 24.8% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,900,414 shares of the company’s stock valued at $15,260,000 after purchasing an additional 378,182 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. grew its stake in Endo International by 3.1% in the first quarter. Diamond Hill Capital Management Inc. now owns 1,348,760 shares of the company’s stock valued at $10,831,000 after purchasing an additional 40,445 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.